PSMD1 and COVID-19: All but one of the 206 study participants who had received one COVID-19 vaccine dose and who participated in the last study visit in May 2021 and two additional COVID-19 vaccine doses up to the present study visit demonstrated an increase in the anti-S1-RBD-SARS-CoV-2 antibody titer (median AU/mL [IQR]: 60 [29–120] vs. 17,614 [11,538–25,000]; p < 0.0001).